BioMarin Pharmaceutical Inc. has reached an agreement with Acqua Wellington North American Equities Fund Ltd. for an equity investment in BioMarin of up to $50 million.
Novato's BioMarin Pharmaceutical develops therapies for life-threatening genetic diseases that presently lack effective treatment options. The company is also developing treatments for patients with severe burns....
Novato's BioMarin Pharmaceutical develops therapies for life-threatening genetic diseases that presently lack effective treatment options. The company is also developing treatments for patients with severe burns....
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In